Benefit-risk analysis for the clinician: 'primum non nocere' revisited-the case for antipsychotics in the treatment of behavioural disturbances in dementia

P. Naarding, M. van Grevenstein, A.T.F. Beekman

    Research output: Contribution to JournalArticleAcademicpeer-review

    Abstract

    The results of clinical trials are often presented in a way that only highlights either the benefits or the risks of the treatment under study. Especially in older age, clinical psychiatric problems are often of complex nature, which requires integrating multiple sources of data to reach clinical decisions. An analytical, decision-making strategy can be of help in arranging the results of various studies in such a way as to aid decision-making. In this paper, we clarify this method using the case of the risks and benefits of using antipsychotics in older people with dementia and behavioural disturbances. Copyright © 2010 John Wiley & Sons, Ltd.
    Original languageEnglish
    Pages (from-to)437-440
    JournalInternational Journal of Geriatric Psychiatry
    Volume25
    Issue number5
    DOIs
    Publication statusPublished - 2010

    Fingerprint

    Dive into the research topics of 'Benefit-risk analysis for the clinician: 'primum non nocere' revisited-the case for antipsychotics in the treatment of behavioural disturbances in dementia'. Together they form a unique fingerprint.

    Cite this